Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth - GBI Research Reports

Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth

Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth - GBI Research Reports
Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth
Published Apr 11, 2011
97 pages — Published Apr 11, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research has released its pharmaceutical report, Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth that provides key data, information and analysis of the major trends and issues affecting the clinical trial market in China. The report provides a comprehensive insight into the reasons for outsourcing clinical trials to China and the key services provided by the CROs of China. The report provides a detailed analysis of the Chinese market in terms of its size, and major service offerings of the CROs in China. The report also discusses the factors that are driving the clinical trial market in China. The report delves into the key documents required by the investigator and the sponsor before, during and after the conduct of clinical trials. It also provides an insight into the government support initiatives in China to encourage clinical trials. The report also provides key alliances and acquisitions between the western CROs and the local CROs of China, and the key trends emerging out of such partnerships. The report also looks into the major challenges that can restrict the growth of the clinical trials market in China. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in house analysis by GBI Researchs team of industry experts.

With increasing cost cutting pressures due to decreasing R&D productivity, patent expiries of blockbusters, drying pipelines and stringent regulations of the western governments, the cost of conducting research in the western world is increasing and in turn is putting immense financial pressures on the big pharma companies. On the other hand, China has developed significant capabilities in drug discovery research to match the western standards, while providing substantial cost advantages of up to 50-60%, and is becoming an attractive option to conduct discovery and preclinical stage research. The availability of a huge talent pool and favorable infrastructure support are also two major advantages in China. Although China controls a very small part of the global discovery research, this share is expected to rise in the future as the western pharmaceuticals realize the need to outsource the maximum possible amount of R&D work to the low cost countries. With discovery research occupying close to one-third of the R&D costs, there is a huge opportunity for significant cost savings.

Scope

The scope of this report includes -
- The need for outsourcing clinical trials to China.
- Trends in clinical trial registration in China and a comparative analysis of clinical trial registration in BRIC countries.
- Analysis of the key drivers that are fueling the growth of the clinical trial market in China.
- Qualitative analysis of the key infrastructural facilities required for conducting clinical trials in China.
- Analysis of key government regulations in China affecting the clinical trial market.
- Study of nine key CROs in the clinical trial services space and their deals/partnerships with western pharma in the clinical trial space.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Compare the key capabilities of major clinical trial service providers with your requirements and optimize your R&D costs.
- Develop market entry and market expansion strategies by identifying the key drivers and challenges in the Chinese market.
- Develop effective strategies to maximize the advantages in China through the understanding of the regulatory environment and government support.
- Understand the regulatory structure in China and key documents required to register clinical trials in

  
Source:
Document ID
GBIHC090MR
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents36
  List of Tables61
  List of Figures72
Emerging Market for Clinical Trials - China Introduction92
  GBI Research Report Guidance101
Emerging Market for Clinical Trials - China Overview1117
  The Clinical Research Process Overview111
    Drug Discovery111
    Pre-Clinical121
    Phase I121
    Phase II121
    Phase III121
    Review and Approval from the Regulatory Agencies121
    Post-marketing Studies121
  Clinical Trial Design and Types131
    Types of Design131
      Parallel Group Trial Design131
      Cross over Trial Design141
      Adaptive Clinical Trial Design152
      Wyeth s Learn and Confirm Model172
  Role of CROs191
  Sponsors of Clinical Trials201
  Intellectual Property Protection in China211
    Article 15211
    Aritcle 20221
    Articles 22 and 23221
    Article 62221
    Articles 48 and 50221
    Article 69(5)221
    Article 5 and 26221
  The Need for Outsourcing Clinical Trials231
    High Risks and Costs Associated With Drug Development231
    Escalating Costs of Clinical Trials241
    Global Increase in the Number of Clinical Trials Conducted251
    Restructuring the R&D251
    Increased Screening Rates during R&D261
    Expiring Patents Pressurize Pharmaceutical Companies to Reduce Costs271
Emerging Market for Clinical Trials China - Clinical Trial Trends2816
  Registration of Phase l Clinical Trials281
  Registration of Phase ll Clinical Trials291
  Registration of Phase lll Clinical Trials301
  Registration of Phase lV Clinical Trials311
  Clinical Trials Registered in 2010321
  Comparative Analysis of Registered Clinical Trials in Brazil, Russia, India and China (BRIC) Countries331
  Comparative Analysis of Population Statistics in BRIC Countries341
  Population Forecast of China351
  Analysis of Epidemiology and Prevalence of Major Diseases in China361
    Number of Recruiting Sites for Major Therapeutics in China361
      Number of Recruiting Sites by Multinational Companies (MNCs) in China371
      Number of Clinical Trials Carried Out By Multinational Companies in China381
      Number of Clinical Trials Carried out by MNC s in Hong Kong391
      Number of Major State Food and Drug Administration (SFDA) Accredited Study Sites in China402
      Number of SFDA Accredited Institutions for Therapeutic Areas422
Emerging Market for Clinical Trials China - Market Environment Characterization4422
  Increase in Growth of Global CRO Market will Foster the Growth of Chinese Clinical Trial Market441
    Increase in Multinational Sites to Conduct Clinical Trials will Drive the Clinical Trial Market in China452
    Access to a Large Patient Population471
    Comparison of Population of Different Countries481
    Patient Availability for Major Diseases491
      Number of Major Infections in China491
      Number of Deaths Occurring by Diseases in China501
      HIV/AIDS511
      Cardiovascular Diseases (CVD)521
      Diabetes531
      Cancer541
      Chronic Obstructive Pulmonary Diseases (COPD)551
    Subject Recruitment and Speed of Trials561
    Cost Comparison China Vs the US561
    Annual Median Salaries of Doctors in China571
    Annual Median Salaries of Doctors in Different Provinces of China581
    Infrastructural Facilities Improve the Clinical Trial Environment591
      Health Care Institutions in China in 2009591
      Growth of Health Care Professionals in China601
    Increase in Number of Graduates in Colleges and Universities of China611
      Number of Graduates Registered in Colleges and Universities611
      Number of Graduates in Medical Colleges621
      Increase in Principal Investigators631
  Market Restraints641
    Slow Regulatory Approvals641
    Insufficient Communication Platform641
    Intellectual Property Issues are not Fully Resolved641
    In depth Training in Good Clinical Practices (GCP) for Health Care Professionals641
  Clinical Trial Market Size in China651
Emerging Market for Clinical Trials China - Regulatory Landscape6615
  Introduction661
    Drug Administration Law661
    Implementing Regulation of Drug Administrative Law671
    Good Clinical Practices (GCP) of Pharmaceutical Products (1999)671
    Work Rules for Clinical Research of Drugs (2000)681
    Structure and Procedure for Monitoring Adverse Drug Reactions in China691
  The Ministry of Health701
  State Food and Drug Administration (SFDA)701
  Clinical Trials Registry China (ChiCTR)711
  Clinical Trial Regulation in China721
    Approval Process for Clinical Trials in China721
    Number of Days Required For Getting the Approval for Clinical Trials (Individual Procedures)731
    Approval Process for Clinical Trials in China for Imported Drugs741
    Number of Days Required For Getting the Approval for Clinical Trials for Imported Drugs (Individual Procedures)751
    Documents Required With the Investigator of Clinical Trials751
      Documents to Be Located In the Files of Investigator before the Commencement of Clinical Trials751
      Documents to Be Located In the Files of Investigator during the Clinical Conduct of Trials761
      Documents to Be Located In the Files of Investigator after Completion of Clinical Trials761
    Documents Required With the Sponsor of Clinical Trials771
      Documents to Be Located In the Files of Sponsor before the Commencement of Clinical Trials771
      Documents to Be Located In the Files of Sponsor during the Clinical Conduct of Trials781
      Documents to Be Located In the Files of Sponsor after Completion of Clinical Trials781
  Recent Regulatory Changes in Clinical Trials791
    Longer lead-times on specified exports791
    Need for Chinese-based applicant.791
  Government Incentives791
  Activity of International Pharmaceutical Companies in China801
Emerging Market for Clinical Trials China - CRO Landscape8112
  Classification of CROs in China811
  Number of CROs in China Based on Types of Services Rendered821
  Acquisitions of Chinese CROs831
  Recent Alliances of Chinese CROs831
  CRO Profiles841
    BO JI Medicine Services Co. Ltd841
      Business Description841
    Giant Med-Pharma Services Inc851
      Business Description851
    InCROM861
      Business Description861
    Pharmaron871
      Business Description871
    Venturepharm Service Group (VPS)881
      Business Description881
    PPD891
      Business Description891
    CCBR-SYNARC901
      Business Description901
    Quintiles911
      Business Description911
    Kendle921
      Business Description921
Emerging Market for Clinical Trials China - Appendix935
  Market Definitions931
  Abbreviations931
  Research Methodology942
    Coverage941
    Secondary Research951
    Primary Research951
    Expert Panel Validation951
  Contact Us961
  Disclaimer961
  Sources962

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth" Apr 11, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Market-for-Clinical-Trials-in-China-Communication-Problems-and-Unresolved-Intellectual-Property-Issues-Restrict-Growth-2115-200>
  
APA:
GBI Research Reports. (2011). Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth Apr 11, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Market-for-Clinical-Trials-in-China-Communication-Problems-and-Unresolved-Intellectual-Property-Issues-Restrict-Growth-2115-200>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.